The next innovations in chimeric antigen receptor T cell immunotherapies for cancer.
| Publication Type | Review |
| Authors | Anupindi K, Malachowski J, Hodson I, Zhu D, June C, Levine B |
| Journal | Cytotherapy |
| Volume | 27 |
| Issue | 7 |
| Pagination | 795-811 |
| Date Published | 05/23/2025 |
| ISSN | 1477-2566 |
| Keywords | Immunotherapy, Adoptive, Receptors, Chimeric Antigen, Neoplasms, T-Lymphocytes, Receptors, Antigen, T-Cell, Immunotherapy |
| Abstract | Chimeric antigen receptor (CAR) T cell therapy has transformed cancer treatment and the field of immunotherapy. Although CAR T cell therapy has demonstrated considerable clinical success for the treatment of B cell malignancies, expanding its therapeutic efficacy and accessibility for other hematological malignancies and solid tumors remains a challenge. Key limitations include manufacturing constraints and therapeutic hurdles, such as CAR T cell persistence, proliferation, tumor trafficking and treatment-related toxicities. To overcome the unique challenges associated with CAR T cell therapy, novel technological advancements in CAR design, delivery, and T cell functionality can be leveraged. This review will explore three innovative approaches: gene editing and silencing, armoring strategies and in vivo CAR gene delivery. These approaches are all aimed at enhancing the accessibility and therapeutic efficacy of CAR T cell therapy in hematological malignancies. |
| DOI | 10.1016/j.jcyt.2025.05.010 |
| PubMed ID | 40542808 |